Status:
COMPLETED
Separate and Combined Extrapancreatic Effects of GIP and GLP-1
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Pancreatectomy; Hyperglycemia
Eligibility:
All Genders
30-75 years
Phase:
NA
Brief Summary
The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secre...
Eligibility Criteria
Inclusion
- Total pancreatectomy
- Caucasians between 30-75 years of age
- Blood haemoglobin \>7.0 mmol/l for males and \>6.5 mmol/l for females
Exclusion
- Pancreatectomy within the last 3 months
- Ongoing chemotherapy or chemotherapy within the last 3 months
- Treatment with GLP-1 receptor agonists within the last 3 months
- Renal impairment (estimated by estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2) and/or albuminuria
- Calcium related disease, hypo-/hyperthyroidism
- Known significant liver disease, plasma alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 × normal value or INR (The international normalised ratio based on prothrombin time) outside the normal range
- Severe arteriosclerotic heart disease or heart failure (New York Heart Association (NYHA) group III or IV)
- Pregnancy and/or breastfeeding
- Use of more than 14 units of alcohol per week or abuse of narcotics
- Any condition that the investigator feels would interfere with trial participation
Key Trial Info
Start Date :
February 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 14 2025
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06895408
Start Date
February 19 2025
End Date
July 14 2025
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark, 2900